Skip to content
2000
Volume 32, Issue 21
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X
file format text download EPUB
file format pdf download PDF
side by side viewer icon HTML

Abstract

Plants have historically been a primary source of medicines due to their diverse molecular and structural composition. Plant metabolism, comprising primary and secondary processes, produces primary metabolites crucial for growth and secondary metabolites, or natural products (NPs), with specific biological functions. These small molecules are instrumental in pharmacology for their ability to penetrate biological barriers and interact with intracellular targets. The structural complexity and limited availability of NPs have led to research focusing on enhancing their diversity through semi-synthesis. In this commentary, examples of various semisynthetic derivatives of NPs obtained through different synthetic strategies, such as organic semi-synthesis or combinatorial chemistry, are cited. Additionally, the importance of developing hybrid molecules based on the combination of two or more distinct pharmacophores is emphasized. This strategy has been widely implemented to obtain new multitarget drugs applicable to the treatment of multifactorial neurodegenerative diseases, where stimulating the cholinergic system by modulating different therapeutic targets is crucial. However, challenges, such as structural complexity, raw material availability, and the need for precise synthetic methods, persist. Innovations in synthetic routes, sustainable harvesting, and biotechnological advances are critical to overcoming these barriers. The integration of omics technologies, green chemistry principles, and global collaboration is essential to maximize the potential of NPs in drug development, ensuring sustainable and efficient production of new therapeutics.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673336208241014102943
2024-10-29
2025-10-10

  • From This Site

    /content/journals/cmc/10.2174/0109298673336208241014102943
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cmc/32/21/CMC-32-21-01.html?itemId=/content/journals/cmc/10.2174/0109298673336208241014102943&mimeType=html&fmt=ahah

References

  1. KrauseJ. TobiG. KulkaM. Discovery, Development, and regulation of natural products.Using Old Solutions to New Problems - Natural Drug Discovery in the 21st Century.London, UKIntechOpen2013Vol. 133510.5772/56424
     [Google Scholar]
  2. BernardiniS. TiezziA. Laghezza MasciV. OvidiE. Natural products for human health: an historical overview of the drug discovery approaches.Nat. Prod. Res.201832161926195010.1080/14786419.2017.135683828748726
     [Google Scholar]
  3. ThakurM. BhattacharyaS. KhoslaP.K. PuriS. Improving production of plant secondary metabolites through biotic and abiotic elicitation.J. Appl. Res. Med. Aromat. Plants20191211210.1016/j.jarmap.2018.11.004
     [Google Scholar]
  4. YangL. WenK.S. RuanX. ZhaoY.X. WeiF. WangQ. Response of plant secondary metabolites to environmental factors.Molecules201823476210.3390/molecules2304076229584636
     [Google Scholar]
  5. NewmanD.J. CraggG.M. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019.J. Nat. Prod.202083377080310.1021/acs.jnatprod.9b0128532162523
     [Google Scholar]
  6. BenetL.Z. HoseyC.M. UrsuO. OpreaT.I. BDDCS, the rule of 5 and drugability.Adv. Drug Deliv. Rev.2016101899810.1016/j.addr.2016.05.00727182629
     [Google Scholar]
  7. CentellesJ. J. ImperialS. Paclitaxel: Descubrimiento, propiedades y uso clínico.Ámbito Farmacéutico.20102946875
     [Google Scholar]
  8. DiasD.A. UrbanS. RoessnerU. A historical overview of natural products in drug discovery.Metabolites20122230333610.3390/metabo202030324957513
     [Google Scholar]
  9. SunQ. WangJ. LiY. ZhuangJ. ZhangQ. SunX. SunD. Synthesis and evaluation of cytotoxic activities of artemisinin derivatives.Chem. Biol. Drug Des.20179051019102810.1111/cbdd.1301628489280
     [Google Scholar]
  10. ReddyM.P. ChowdaryN.V. Novel process for the preparation of sorafenib.Patent WO2009054004A22007
  11. ChavaS. GorantlaS.R.A. IndukuriV.S.K. MoturuV.R.K. JamjanamS.R. ShamakuraA.K.R. GunaparthiS.K. NekkantiV.V.S. Novel processes for the preparation of vemurafenib.Patent WO2015075749A12015
  12. MeiY. YeQ. YangB. XiaoL. GeH. The novel synthesis of Ataluren.Patent CN106279057A2017
  13. EkinciD. ŞentürkM. KüfrevioğluÖ.İ. Salicylic acid derivatives: Synthesis, features and usage as therapeutic tools.Expert Opin. Ther. Pat.201121121831184110.1517/13543776.2011.63635422098318
     [Google Scholar]
  14. ArpiccoS. StellaB. SchiavonO. MillaP. ZonariD. CattelL. Preparation and characterization of novel poly(ethylene glycol) paclitaxel derivatives.Int. J. Pharm.2013454265365910.1016/j.ijpharm.2013.05.02723701999
     [Google Scholar]
  15. Díaz-QuirozD.C. Cardona-FélixC.S. Viveros-CeballosJ.L. Reyes-GonzálezM.A. BolívarF. OrdoñezM. EscalanteA. Synthesis, biological activity and molecular modelling studies of shikimic acid derivatives as inhibitors of the shikimate dehydrogenase enzyme of Escherichia coli.J. Enzyme Inhib. Med. Chem.201833139740410.1080/14756366.2017.142212529363372
     [Google Scholar]
  16. BacheM. BernhardtS. PassinS. WichmannH. HeinA. ZschornakM.P. KapplerM. TaubertH. PaschkeR. VordermarkD. Betulinic acid derivatives NVX-207 and B10 for treatment of glioblastoma--an in vitro study of cytotoxicity and radiosensitization.Int. J. Mol. Sci.20141511197771979010.3390/ijms15111977725361208
     [Google Scholar]
  17. DeckerM. Design of hybrid molecules for drug development.Design of Hybrid Molecules for Drug DevelopmentElsevier Science20171st ed
     [Google Scholar]
  18. WilliamsD.H. StoneM.J. HauckP.R. RahmanS.K. Why are secondary metabolites (natural products) biosynthesized?J. Nat. Prod.19895261189120810.1021/np50066a0012693613
     [Google Scholar]
  19. Mesa VanegasA.M. Una visión histórica en el desarrollo de fármacos a partir de productos naturales.Rev. Mex. Cienc. Farm.20174831627
     [Google Scholar]
  20. MunafóJ.P. BiscussiB. ObiolD. CostabelM. BouzatC. MurrayA.P. AntolliniS. New multitarget molecules derived from caffeine as potentiators of the cholinergic system.ACS Chem. Neurosci.2024155994100910.1021/acschemneuro.3c0071038407056
     [Google Scholar]
  21. MishraP. KumarA. PandaG. Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer’s disease (1998–2018).Bioorg. Med. Chem.201927689593010.1016/j.bmc.2019.01.02530744931
     [Google Scholar]
  22. StanciuG.D. LucaA. RusuR.N. BildV. Beschea ChiriacS.I. SolcanC. BildW. AbabeiD.C. Alzheimer’s disease pharmacotherapy in relation to cholinergic system involvement.Biomolecules20191014010.3390/biom1001004031888102
     [Google Scholar]
  23. SantiM. SancinetoL. NascimentoV. Braun AzeredoJ. OrozcoE.V.M. AndradeL.H. GrögerH. SantiC. Flow biocatalysis: A challenging alternative for the synthesis of APIs and natural compounds.Int. J. Mol. Sci.202122399010.3390/ijms2203099033498198
     [Google Scholar]
  24. RienzoM. JacksonS.J. ChaoL.K. LeafT. SchmidtT.J. NavidiA.H. NadlerD.C. OhlerM. LeavellM.D. High-throughput screening for high-efficiency small-molecule biosynthesis.Metab. Eng.20216310212510.1016/j.ymben.2020.09.00433017684
     [Google Scholar]
  25. TianR. LiY. XuJ. HouC. LuoQ. LiuJ. Recent development in the design of artificial enzymes through molecular imprinting technology.J. Mater. Chem. B Mater. Biol. Med.202210356590660610.1039/D2TB00276K35748432
     [Google Scholar]
  26. DaiX. ShenL. Advances and trends in omics technology development.Front. Med. (Lausanne)2022991186110.3389/fmed.2022.91186135860739
     [Google Scholar]
  27. PaananenJ. FortinoV. An omics perspective on drug target discovery platforms.Brief. Bioinform.20202161937195310.1093/bib/bbz12231774113
     [Google Scholar]
  28. MussoF. GutierrezV. FaraoniM.B. VolpeM.A. Allylic oxidation of α-pinene over supported SeO2-based catalysts.Lat. Am. Appl. Res.202353428729310.52292/j.laar.2023.1061
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673336208241014102943
Loading
Commentary on the Obtention of Semi-synthetic Derivatives from Natural Products for Medicinal Applications: Advances, Challenges, and Perspectives
Curr. Med. Chem. 32, 4147 (2025); https://doi.org/10.2174/0109298673336208241014102943
/content/journals/cmc/10.2174/0109298673336208241014102943
/content/journals/cmc/10.2174/0109298673336208241014102943
Loading

Data & Media loading...


  • Article Type:     Editorial
Keyword(s): bioactive compounds; drug design; metabolites; Natural products (NPs); semi-synthesis; sustainable production

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test